Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis.
Josephine HarringtonAnne S HellkampKenneth W MahaffeyGuenter BreithardtJonathan L HalperinGraeme J HankeyRichard C BeckerChristopher C NesselScott D BerkowitzKeith A A FoxDaniel E SingerShaun G GoodmanManesh R PatelJonathan P PicciniPublished in: Journal of the American Heart Association (2024)
DAOH did not identify a treatment difference between patients randomized to rivaroxaban versus warfarin. This may be driven in part by the low overall event rates in atrial fibrillation anticoagulation trials, which leads to substantial left skew in measures of DAOH.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- catheter ablation
- left atrial
- direct oral anticoagulants
- left atrial appendage
- heart failure
- end stage renal disease
- percutaneous coronary intervention
- newly diagnosed
- ejection fraction
- venous thromboembolism
- open label
- double blind
- peritoneal dialysis
- emergency department
- randomized controlled trial
- coronary artery disease
- phase ii
- patient reported
- phase iii
- adverse drug
- acute care
- pulmonary embolism
- mitral valve
- combination therapy
- drug induced